Clinical Trial Update: Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating arsenic trioxide delivered via transarterial chemoembolization for hepatocellular carcinoma, focusing on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: First Hospital of China Medical University | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: UNKNOWN